Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

An association between increased serum-soluble interleukin-2 receptors and a disturbance in muscle force in schizophrenic patients.

Rapaport MH, Caligiuri MP, Lohr JB.

Prog Neuropsychopharmacol Biol Psychiatry. 1997 Jul;21(5):817-27.

PMID:
9278953
3.

A disturbance in the control of muscle force in neuroleptic-naive schizophrenic patients.

Caligiuri MP, Lohr JB.

Biol Psychiatry. 1994 Jan 15;35(2):104-11.

PMID:
7909452
4.

Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients.

Rapaport MH, McAllister CG, Kim YS, Han JH, Pickar D, Nelson DL, Kirch DG, Paul SM.

Biol Psychiatry. 1994 May 15;35(10):767-71.

PMID:
8043705
5.

Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder.

O'Donnell MC, Catts SV, Ward PB, Liebert B, Lloyd A, Wakefield D, McConaghy N.

Psychiatry Res. 1996 Dec 20;65(3):171-8.

PMID:
9029665
6.
7.

Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins.

Rapaport MH, Torrey EF, McAllister CG, Nelson DL, Pickar D, Paul SM.

Eur Arch Psychiatry Clin Neurosci. 1993;243(1):7-10.

PMID:
8399412
8.

Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia.

Müller N, Empl M, Riedel M, Schwarz M, Ackenheil M.

Eur Arch Psychiatry Clin Neurosci. 1997;247(6):308-13.

PMID:
9477010
9.

Motor mechanisms in schizophrenic patients with tardive dyskinesia.

Vrtunski PB, Alphs LD, Meltzer HY.

Psychiatry Res. 1994 Oct;54(1):71-86.

PMID:
7701030
10.
11.

Serum levels of soluble interleukin-2 receptor in patients with ANCA-associated vasculitis.

Arranz O, Ara J, Rodríguez R, Saurina A, Mirapeix E, Darnell A.

J Nephrol. 2000 Jan-Feb;13(1):59-64.

PMID:
10720216
12.

Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.

Hildesheim A, Schiffman MH, Tsukui T, Swanson CA, Lucci J 3rd, Scott DR, Glass AG, Rush BB, Lorincz AT, Corrigan A, Burk RD, Helgesen K, Houghten RA, Sherman ME, Kurman RJ, Berzofsky JA, Kramer TR.

Cancer Epidemiol Biomarkers Prev. 1997 Oct;6(10):807-13.

13.

Serum levels of soluble interleukin-2 receptor in patients with various renal diseases.

Sugimoto H, Hashimoto N, Suzuki S, Gejyo F.

Tohoku J Exp Med. 1998 Apr;184(4):311-6.

14.
15.
16.

Seborrhea and persistent tardive dyskinesia.

Sandyk R.

Int J Neurosci. 1990 Feb;50(3-4):223-6.

PMID:
2148314
17.

Serum vitamin B6 in schizophrenic and schizoaffective patients with and without tardive dyskinesia.

Miodownik C, Lerner V, Cohen H, Kotler M.

Clin Neuropharmacol. 2000 Jul-Aug;23(4):212-5.

PMID:
11020126
18.

Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia.

Bresee C, Rapaport MH.

Int J Neuropsychopharmacol. 2009 Jul;12(6):861-5. doi: 10.1017/S1461145709000315. Epub 2009 Apr 15.

PMID:
19366488
19.

COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy.

Müller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackenheil M, Möller HJ, Gruber R, Riedel M.

Eur Arch Psychiatry Clin Neurosci. 2004 Feb;254(1):14-22.

PMID:
14991374
20.

Serum evaluation of the balance between soluble interleukin-2 and interleukin-4 receptors.

Fujita N, Okamoto Y, Gotoh Y, Yada Y, Suzuki Y, Ando T, Togari H, Nishida M.

Cytokine. 2005 Nov 3;32(3-4):143-8. Epub 2005 Oct 13.

PMID:
16226465

Supplemental Content

Support Center